Work

Supplementary Data 4 from Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition

Year: 2023

Type: supplementary-materials

Abstract: Supplemental figure 4: (A) Mia PaCa2 xenograft tumor volume plotted over time for mice that had no treatment or abemaciclib treatment daily for 9 days. (B) Graphical representation of tumor volume (left) in no treatment and abemaciclib treated mice with n=5, two tumors per mice. All mice, including one outlier mouse in the abemaciclib arm, shown for comparison to Figure 5. Graphical representation of tumor weights after sacrifice are shown, including one outlier mouse in the abemaciclib arm, shown for comparison to Figure 5 (right). (C) Xenograft tumors from all experimental arms were collected at day 69 at the end of the experiment and harvested for western blot analysis, and probed for pRb, ser 780. Quantification of the western blot is shown above the blot.

DOI: 10.1158/1541-7786.22516450

Authors: Teena Dhir, Christopher W. Schultz, Aditi Jain, Samantha Z. Brown, Alex Haber, Austin Goetz, Chunhua Xi, Gloria H. Su, Liang Xu, James Posey, Wei Jiang, Charles J. Yeo, Talia Golan, Michael J. Pishvaian, Jonathan R. Brody

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362637482

Cites:

Cited by:

Related to: 10